PCI BIOTECH HOLDING ASA (PCIB.OL) Stock Income Statement
OSL:PCIB - Euronext Oslo - NO0010405640 - Common Stock - Currency: NOK
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 6.74M | 2.99M | 4.75M | 6.27M | 7.37M | |||
| Operating Expenses | 24.69M | 25.23M | 61.20M | 92.30M | 89.49M | |||
| Research and Development | 16.06M | 15.63M | 44.76M | 71.71M | 75.57M | |||
| Selling, General, and Administrative Expenses | 8.63M | 9.60M | 16.44M | 20.59M | 13.92M | |||
| Operating Income | -17.95M | -22.24M | -56.45M | -86.03M | -82.12M | |||
| Interest Income/Expense | 1.54M | 1.93M | 1.11M | 551.00K | 1.45M | |||
| Other Income/Expense | N/A | 0.00 | 242.00K | -2.91M | 8.43M | |||
| Income Before Taxes | -16.42M | -20.32M | -55.09M | -88.39M | -72.24M | |||
| Income Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Net Income | -16.42M | -20.32M | -55.09M | -88.39M | -72.24M | |||
| EBITDA | -17.65M | -21.87M | -50.04M | -83.49M | -79.91M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.44 | -0.54 | -1.48 | -2.37 | -1.94 | |||
| Statistics | ||||||||
| Profit Margin | -243.76% | -679.43% | -1159.89% | -1409.07% | -980.44% | |||
| Operating Profit Margin | -266.59% | -743.85% | -1188.36% | -1371.42% | -1114.56% | |||
All data in NOK